ABSTRACT
The everolimus-eluting bioresorbable vascular scaffolds (BVSs) are designed to provide comparable radial strength and anti-restenotic efficacy to metallic drug-eluting stents (DESs) in the first year after implantation and superior long-term benefits after the scaffold bioresorbs. ABSORB China is the first BVSs randomized trial with a powered primary endpoint of angiographic in-segment late loss at 1 year designed for regulatory approval of BVSs in China. ABSORB China is a prospective, randomized, active-controlled, open-label, multicenter trial designed to evaluate the safety and efficacy of BVSs compared with cobalt-chromium everolimus-eluting stents (CoCr-EES). The primary endpoint of ABSORB China was to determine if BVSs was non-inferior to CoCr-EES in angiographic in-segment late loss (LL) at 1 year in the per-treatment-evaluable (PTE) population. Angiographic secondary endpoints included in-device LL, in-device and in-segment minimal lumen diameter (MLD), in-device and in-segment " diameter stenosis (DS), and in-device and in-segment binary restenosis (ABR).
